Jelani C. Zarif

Jelani C. Zarif

Auto-generated profile, based on publicly available information

Jelani C. Zarif

Bloomberg∼Kimmel Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
EREmily M. Rencsok
Emily M. Rencsok
LBLatifa A. Bazzi
Latifa A. Bazzi
RMRana R. McKay
Rana R. McKay
FHFranklin W. Huang
Franklin W. Huang
AFAdam Friedant
Adam Friedant
LMLorelei A. Mucci
Lorelei A. Mucci
Although there are considerable racial and ethnic disparities in prostate cancer incidence and mortality in the U.S. and globally, clinical trials often do not reflect disease incidence across racial and ethnic subgroups. This study aims to comprehensively review the reporting of race and ethnicity data and the representation of race and ethnicity across prostate cancer treatment-, prevention-, and screening-based clinical trials. Seventy-two global phase III and IV prevention, screening, and treatment prostate cancer clinical trials with enrollment start dates between 1987 and 2016 were analyzed in this study, representing a total of 893,378 individual trial participants. Availability and representation of race and ethnicity data by trial funding type, temporal changes in the racial/ethnic diversity of participants, and geographic representation of countries were assessed. Of the 72 trials analyzed, 59 (81.9%) had available race data, and 11 (15.3%) of these trials additionally reported ethnicity. Of the trials reporting data, participants were overwhelmingly white men (with the highest proportion in U.S. non-publicly funded trials), comprising over 96% of the study population. The proportion of white participants in prostate cancer clinical trials has remained at over 80% since 1990. Geographically, Africa and the Caribbean were particularly underrepresented with only 3% of countries included. Trial participants continue to be majority white despite the known racial disparities in prostate cancer clinical outcomes. Current and future trials must use novel recruitment strategies to ensure enrollment of underrepresented men; targeting the inclusion of African and Caribbean medical centers is crucial to achieve equity in representation.

1 July 2016 in BioTechniques
Verified
Journal Article
Open access
JZJelani C. Zarif
Jelani C. Zarif
JHJames R. Hernandez
James R. Hernandez
JVJames E. Verdone
James E. Verdone
SCScott P. Campbell
Scott P. Campbell
CDCharles G. Drake
Charles G. Drake
KPKenneth J. Pienta
Kenneth J. Pienta
There are currently several in vitro strategies to differentiate human CD14+ monocytes isolated from peripheral blood mononuclear cells (PBMCs) into the M1 or M2 macrophage cell types. Each cell ty... MONOCYTES GOING THROUGH A PHASE Classical circulating CD14+ human monocytes can differentiate into M1 or M2 macrophages or monocyte-derived dendritic cells (moDCs) at sites of infection based on wh...

1 July 2019 in European Urology Oncology
Verified
Journal Article
Closed access
JZJelani C. Zarif
Jelani C. Zarif
JVJavier A. Baena-Del Valle
Javier A. Baena-Del Valle
JHJessica L. Hicks
Jessica L. Hicks
CHChristopher M. Heaphy
Christopher M. Heaphy
IVIgor Vidal
Igor Vidal
AMAngelo M. De Marzo
Angelo M. De Marzo

26 April 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
MPMonali Praharaj
Monali Praharaj
FSFan Shen
Fan Shen
ALAlex J. Lee
Alex J. Lee
LZLiang Zhao
Liang Zhao
TNThomas R. Nirschl
Thomas R. Nirschl
JZJelani C. Zarif
Jelani C. Zarif
Glutamine metabolism in tumor microenvironments critically regulates antitumor immunity. Using the glutamine-antagonist prodrug JHU083, we report potent tumor growth inhibition in urologic tumors by JHU083-reprogrammed tumor-associated macrophages (TAMs) and tumor-infiltrating monocytes. We show JHU083-mediated glutamine antagonism in tumor microenvironments induced by TNF, proinflammatory, and mTORC1 signaling in intratumoral TAM clusters. JHU083-reprogrammed TAMs also exhibited increased tumor cell phagocytosis and diminished proangiogenic capacities. In vivo inhibition of TAM glutamine consumption resulted in increased glycolysis, a broken tricarboxylic acid (TCA) cycle, and purine metabolism disruption. Although the antitumor effect of glutamine antagonism on tumor-infiltrating T cells was moderate, JHU083 promoted a stem cell–like phenotype in CD8+ T cells and decreased the abundance of regulatory T cells. Finally, JHU083 caused a global shutdown in glutamine-utilizing metabolic pathways in tumor cells, leading to reduced HIF-1α, c-MYC phosphorylation, and induction of tumor cell apoptosis, all key antitumor features. Altogether, our findings demonstrate that targeting glutamine with JHU083 led to suppressed tumor growth as well as reprogramming of immunosuppressive TAMs within prostate and bladder tumors that promoted antitumor immune responses. JHU083 can offer an effective therapeutic benefit for tumor types that are enriched in immunosuppressive TAMs.

3 July 2014 in OncoImmunology
Verified
Journal Article
Open access
JZJelani C Zarif
Jelani C Zarif
RTRussell Taichman
Russell Taichman
KPKenneth J Pienta
Kenneth J Pienta
Cancer continues to be the major cause of morbidity and death of more than 500,000 people in the US annually. Alternatively activated macrophages (M2 macrophages or TAMs) can facilitate tumor invasiveness and metastasis. As an invasive species in the tumor microenvironment, they provide an ideal therapeutic target.

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
RMRana R. McKay
Rana R. McKay
TGTheresa Gold
Theresa Gold
JZJelani C. Zarif
Jelani C. Zarif
ICIlkania M. Chowdhury-Paulino
Ilkania M. Chowdhury-Paulino
AFAdam Friedant
Adam Friedant
LMLorelei A. Mucci
Lorelei A. Mucci
Prostate cancer disproportionately affects racial and ethnic minority populations. Reasons for disparate outcomes among minority patients are multifaceted and complex, involving factors at the patient, provider, and system levels. Although advancements in our understanding of disease biology have led to novel therapeutics for men with advanced prostate cancer, including the introduction of biomarker-driven therapeutics, pivotal translational studies and clinical trials are underrepresented by minority populations. Despite attempts to bridge the disparities gap, there remains an unmet need to expand minority engagement and participation in clinical trials to better define the impact of therapy on efficacy outcomes, quality of life, and role of biomarkers in diverse patient populations. The IRONMAN registry (ClinicalTrials.gov identifier: NCT03151629 ), a global, prospective, population-based study, was borne from this unmet medical need to address persistent gaps in our knowledge of advanced prostate cancer. Through integrated collection of clinical outcomes, patient-reported outcomes, epidemiologic data, and biospecimens, IRONMAN has the goal of expanding our understanding of how and why prostate cancer outcomes differ by race and ethnicity. To this end, the Diversity Working Group of the IRONMAN registry has developed informed strategies for site selection, recruitment, engagement and retention, and trial design and eligibility criteria to ensure broad inclusion and needs awareness of minority participants. In concert with systematic strategies to tackle the complex levels of disparate care, our ultimate goal is to expand minority engagement in clinical research and bridge the disparities gap in prostate cancer care.